logo
Defense Spending Could Protect Your Investment Portfolio

Defense Spending Could Protect Your Investment Portfolio

Forbesa day ago
The U.S. defense industry is emerging as one of the most resilient sectors for investors. Amid global instability and rising geopolitical tensions, American policymakers are displaying a unique commitment to military strength. The recent passage of President Trump's 'One Big Beautiful Bill', a sweeping piece of legislation that pushes U.S. defense spending to historic highs, and a newly agreed upon EU – U.S. trade deal underscores this trend. The bill adds $150 billion in new funding to the Department of Defense, bringing total projected spending for the 2026 fiscal year to over $1 trillion. On top of that, the EU has committed to over $600 billion of military equipment procurement in the coming years. The signal to markets is undeniable: defense is a national and global priority.
For investors, this presents an opportunity. Massive new capital is now earmarked for shipbuilding, advanced munitions, next-generation aircraft, and a new missile defense system dubbed the 'Golden Dome.' Defense stocks, long considered cyclical or defensive, may now be positioned for long-term structural growth. Interestingly, this surge in spending comes even as U.S. military expenditures, as a share of GDP, sit at multi-decade lows. According to the Stockholm International Peace Research Institute (SIPRI), global defense spending has climbed 37% over the past decade, but America's share of that growth has not kept pace with its expanding economy. In short: U.S. defense spending is climbing fast in absolute terms, but relative to our economic size, there's still plenty of runway ahead.
TOPSHOT - An US-made MIM-104 Patriot surface-to-air missile is launched during a live fire exercise at the Chiupeng missile base in Pingtung county on August 20, 2024. (Photo by Sam Yeh / AFP) (Photo by SAM YEH/AFP via Getty Images) AFP via Getty Images
Ongoing wars in Europe and the Middle East and intensifying tensions in the Indo-Pacific have forced governments across the globe to rethink their defense postures. In Europe, Russia's continued aggression in Ukraine has led to a dramatic increase in defense budgets across NATO member states. The 2% GDP target for defense spending has given way to a 5%+ target for European members, meaning our allies are finally putting their money where their mouth is – although those expenditures are far from guaranteed. For context, in 2024, the U.S. spent roughly $3,000 per citizen on national defense, more than four times what most European nations spent, according to an article from Barron's . In Europe that number needs to rise meaningfully if they're going to hit their NATO commitments.
The Middle East is increasingly unstable. U.S. involvement in ongoing conflicts in the region, including efforts to deter Iran's nuclear program and manage the persistent tensions between Israel and Palestine, continues to highlight the need for advanced missile defense systems, precision munitions, and rapid deployment capabilities.
The conflict also highlights the expenses associated with war. Every rocket fired comes with a price tag and restocking munitions is expensive, especially when a conflict is hot and countries can't afford to wait for supplies.
The conflict in the Middle East is also indirectly expensive in that it introduces significant volatility into global oil markets. Iran, as a key OPEC member, controls the northern side of the Strait of Hormuz, through which roughly 20% of the world's petroleum supply passes. Any disruption here carries both economic and strategic consequences - further justifying elevated defense spending.
Meanwhile, tensions in the Indo-Pacific region continue to build. China's assertiveness around Taiwan and the South China Sea places it in direct competition with U.S. naval and diplomatic interests. The need to prepare for a potential conflict in the region has subtly been called to the forefront via Trump's recent focus on shipbuilding and other maritime industries. U.S. naval power is extremely important if we were to see a real conflict develop here, but we need more ships. The U.S. market share in shipbuilding has plummeted to just 0.13% as of 2023, down from 5% in the 1970s, according to the U.S. Naval Institute. In contrast, China, Japan, and South Korea now account for over 90% of global shipbuilding capacity. As a result, the U.S. is more reliant on allies and commercial partnerships than ever before - a vulnerability that further underscores the need for investment.
The international dimension of rising defense spending adds a powerful tailwind for U.S. contractors. In 2024, the U.S. Department of State reported that global arms transfers for the U.S. reached nearly $118 billion, and $97 billion of that was funded directly by U.S. allies and partners. American dominance in foreign military sales is accelerating, not just because of technological superiority, but because of interoperability. As Europe, the Middle East, and Asia expand their defense budgets, they are prioritizing systems that integrate seamlessly with U.S. platforms. Whether it's the F-35 fighter jet or the Patriot missile system, American defense tech is becoming the global standard.
This shift has economic implications as well. Defense remains one of the few areas where the U.S. still plays a leading role in high-value manufacturing, a strategic lever in our otherwise service-dominated economy. Arms exports give the U.S. a trade advantage, especially as reducing the trade deficit remains a priority for the Trump administration. The recently finalized EU-U.S. trade deal, which lowered blanket tariffs from 30% to 15%, also includes a pledge of $600 billion in EU military procurement. While the real flow of capital will depend on each country's budget realities, demographics, and political might, the rhetoric alone has been enough to push European defense stocks lower. The market is betting the major U.S. defense contractors, commonly referred to as the primes, will ultimately be the benefactors.
Between 2020 and 2024, the U.S. accounted for 43% of all global arms exports, according to the Stockholm International Peace Research Institute. Key buyers include Saudi Arabia, Japan, Australia, and EU nations - many of which are now aiming for defense spending levels of 3–5% of GDP. For major U.S. firms like Lockheed Martin (LMT), Northrop Grumman (NOC), and RTX Corp. (RTX), this means multibillion-dollar order backlogs and increased income diversification. It also acts as a hedge against domestic budget volatility, reinforcing the fact that U.S. contractors don't need to rely solely on Washington to grow.
OGDEN, UT - MARCH 15: A F-35 fighter jet take-offs for a training mission at Hill Air Force Base on March 15, 2017 in Ogden, Utah. Hill is the first Air Force base to get combat ready F-35's. They currently have 17 that might be deployed in the fight against terrorism and ISIS in the near future. (Photo by) Getty Images The Autonomous Future of Defense
A growing portion of new defense dollars is being directed not just at traditional weaponry, but at artificial intelligence, autonomy, and next-generation battlefield technology. While tanks and missiles still matter, it's AI, drones, and predictive analytics that will define the next phase of military dominance. Companies like Anduril Industries are at the forefront of this transformation. Their autonomous drone systems, battlefield command software, and AI surveillance tools are redefining how militaries perform in combat environments. The basis for all current and future R&D is that the U.S. military needs technology that is mass-producible and entirely replaceable. Unmanned and easily replaceable aircraft are a no-brainer for potential future conflicts.
Meanwhile, Palantir Technologies (PLTR) continues to expand its work with the Department of Defense, building decision-intelligence platforms that help military leaders simulate outcomes and deploy resources more efficiently. These capabilities aren't theoretical -they're already being used in logistics, counterterrorism, and battlefield planning across several branches of the U.S. military. The software-first approach is here to stay. Defensive Cybersecurity
Beyond the battlefield, the digital domain is just as critical. Companies like Palo Alto Networks (PANW), Fortinet (FTNT), and CrowdStrike (CRWD) are playing crucial roles behind the scenes, working alongside defense contractors to secure U.S. military networks and infrastructure. Their platforms are already being used to detect foreign intrusions, prevent ransomware attacks, and build cyber resilience across key defense systems. As cyberattacks from nation-state actors continue to escalate, the Pentagon is steadily shifting a greater portion of its IT and cybersecurity budget toward these firms, viewing them as essential partners in modern warfare. Tanks, aircraft, and ships are worthless if you can't secure the digital infrastructure required for operations.
This photograph hsow the logo of the US big data analytics software company Palantir Technologies during the World Economic Forum (WEF) annual meeting in Davos, on January 23, 2025. (Photo by Fabrice COFFRINI / AFP) (Photo by FABRICE COFFRINI/AFP via Getty Images) AFP via Getty Images
And then there's SpaceX. Its Starlink satellite network has become essential for battlefield communications, notably in Ukraine, and its ability to launch defense communications into low-Earth orbit has made the company indispensable to Pentagon strategy. The militarization of space is no longer a sci-fi concept - it's a live and growing budget category. Taken together, these companies represent a shift from defense as a manufacturing industry to one centered around software, autonomy, and connected systems. Investors looking to position themselves for the next decade of military innovation would be wise to watch not only the legacy names - but also the disruptors. Parting Thoughts
Ultimately, investing in the defense sector isn't just about capitalizing on geopolitical unrest - it's about understanding the structural realignment of global priorities. Defense is a central pillar of economic, technological, and industrial strategy. New legislation in the U.S. and international military spending commitments signal a paradigm shift. Multiyear visibility into global defense spending is music to the ears of the legacy contractors. Rising players in autonomous systems, cybersecurity, and satellite communications are building out the next generation of military infrastructure. There's lots to be excited about, and investors looking for durable tailwinds in a shifting global order should take a look across the entire defense spectrum.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

Yahoo

time18 minutes ago

  • Yahoo

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio

US securities regulator announces AI task force
US securities regulator announces AI task force

Yahoo

time18 minutes ago

  • Yahoo

US securities regulator announces AI task force

(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Yahoo

time18 minutes ago

  • Yahoo

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store